Chronic kidney disease and statins: Improving cardiovascular outcomes

Current Atherosclerosis Reports

Volumn 11, Issue 4, 2009, Pages 301-308

  Walker, D Benson ^a   Walker, Thanh Jennifer ^a   Jacobson, Terry A ^a  

^a Office of Health Promotion and Disease Prevention   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ATORVASTATIN; CHOLESTEROL ACYLTRANSFERASE; CHOLESTEROL ESTER TRANSFER PROTEIN; EZETIMIBE PLUS SIMVASTATIN; FLUINDOSTATIN; FOSINOPRIL; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LOW DENSITY LIPOPROTEIN CHOLESTEROL; MEVINOLIN; PHOSPHATIDYLCHOLINE STEROL ACYLTRANSFERASE; PLACEBO; PRAVASTATIN; ROSUVASTATIN; SIMVASTATIN; VERY LOW DENSITY LIPOPROTEIN;

CARDIOVASCULAR DISEASE; CHOLESTEROL METABOLISM; CHRONIC KIDNEY DISEASE; CLINICAL TRIAL; DISEASE SEVERITY; DRUG DOSE COMPARISON; DRUG DOSE REDUCTION; DRUG DOSE TITRATION; DRUG EXCRETION; DRUG SAFETY; DYSLIPIDEMIA; GLOMERULUS FILTRATION RATE; HEART PROTECTION; HEMODIALYSIS; HUMAN; HYPERTRIGLYCERIDEMIA; ISCHEMIC HEART DISEASE; KIDNEY DISEASE; KIDNEY TRANSPLANTATION; MICROALBUMINURIA; MYOPATHY; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; PATHOGENESIS; PRIMARY PREVENTION; PROTEINURIA; RENAL PROTECTION; REVIEW; RHABDOMYOLYSIS; RISK REDUCTION;

DYSLIPIDEMIAS; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; KIDNEY DISEASES;

EID: 67649118114     PISSN: 15233804     EISSN: None     Source Type: Journal    
DOI: 10.1007/s11883-009-0046-2     Document Type: Review

References (29)

1. Sarnak MJ, Levey AS, Schoolwerth, et al.: Kidney disease as a risk factor for development of cardiovascular disease: A statement from the American Heart Association on Kidney in Cardiovascular Disease, High Blood Pressure Research, Clinical Cardiology, and Epidemiology and Prevention. Circulation 2003, 108:2154-2169.
2. Rashidi A, Sehgal AR, Rahman M, et al.: The case for chronic kidney disease, diabetes mellitus, and myocardial infarction being equivalent risk factors for cardiovascular mortality in patients older than 65 years. Am J Cardiol 2008, 102:1668-1673.
3. Tonelli M, Wiebe N, Culleton B, et al.: Chronic kidney disease and mortality risk: A systematic review. J Am Soc Nephrol 2006, 17:2034-2047.
4. Parfrey PS, Foley RN, Harnett JD, et al.: Outcome and risk factors of ischemic heart disease in chronic uremia. Kidney Int 1996, 49:1428-1434.
5. Muntner P, He J, Astor BC, et al.: Traditional and nontraditional risk factors predict coronary heart disease in chronic kidney disease: results from the Atherosclerosis Risk in Communities Study. J Am Soc Nephrol 2005, 16:529-538.
6. National Kidney Foundation: K/DOQI clinical practice guidelines for chronic kidney disease: Evaluation, classification and stratification. Am J Kidney Dis 2002, 39(2 Suppl 1):S1-S266.
7. Vaziri ND: Dyslipidemia of chroniT renal failure: the nature, mechanisms, and potential consequences. Am J Physiol Renal Physiol 2006, 290:262-272.
8. Chan DT, Irish AB, Dogra GK, et al.: Dyslipidaemia and cardiorenal disease: Mechanisms, therapeutic opportunities and clinical trials. Atherosclerosis 2008, 196:823-834.
9. Cheung AK, Parker CJ, Ren K, et al.: Increased lipase inhibition in uremia: Identification of pre-beta-HDL as a major inhibitor in normal and uremic plasma. Kidney Int 1996, 49:1360-1371.
10. Prinsen BH, De Sain-Van Der Velden MG, de Koning EJ, et al.: Hypertriglyceridemia in patients with chronic renal failure: Possible mechanisms. Kidney Int Suppl 2003, S121-S124.
11. Diercks GF, Janssen WM, Van Boven AJ, et al.: Rationale, design, and baseline characteristics of a trial of prevention of cardiovascular and renal disease With fosinopril and pravastatin in nonhypertensive, nonhypercholesterolemic subjects with microalbuminuria (the Prevention of REnal and Vascular ENdstage Disease Intervention Trial [PREVEND IT]). Am J Cardiol 2000, 86:635-638.
12. Wanner C, Krane V, Marz W, et al.: Atorvastatin in patients with type 2 diabetes mellitus undergoing hemodialysis. N Engl J Med 2005, 353:238-248.
13. Heart Protection Study Collaborative Group: MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20,536 high-risk individuals: A randomised placebo-controlled trial. Lancet 2002, 360:7-22.
14. Tonelli M, Isles C, Craven T, et al.: Effect of pravastatin on rate of kidney function loss in people with or at risk for coronary disease. Circulation 2005, 112:171-178.
15. Tonelli M, Moye L, Sacks FM, et al.: Pravastatin for secondary prevention of cardiovascular events in persons with mild chronic renal insufficiency. Ann Intern Med 2003, 138:98-104.
16. Shepherd J, Kastelein JJ, Bittner V, et al.: Intensive lipid lowering with atorvastatin in patients with coronary heart disease and chronic kidney disease. J Am Coll Cardiol 2008, 51:1448-1454.
17. Shepherd J, Kastelein JJ, Bittner V, et al.: Intensive lipid lowering with atorvastatin in patients with coronary artery disease, diabetes, and chronic kidney disease. Mayo Clin Proc 2008, 83:870-879.
18. Holdaas H, Fellstrom B, Jardine AG, et al.: Effect of fluvastatin on cardiac outcomes in renal transplant recipients: A multicentre, randomised, placebo-controlled trial. Lancet 2003, 361:2024-2031.
19. Wanner C, Krane V, Marz W, et al.: Atorvastatin in patients with type 2 diabetes mellitus undergoing hemodialysis. N Engl J Med 2005, 353:238-248.
20. Fellstrom BC, Jardine AG, Schmieder RE, et al.: Rosuvastatin and cardiovascular events in patients undergoing hemodialysis. N Engl J Med 2009, 360:1395-1407.
21. Seliger SL, Weiss NS, Gillen DL, et al.: HMG-CoA reductase inhibitors are associated with reduced mortality in ESRD patients. Kidney Int 2002, 61:297-304.
22. Andreucci VE, Fissell RB, Bragg-Gresham JL, et al.: Dialysis Outcomes and Practice Patterns Study (DOPPS) data on medications in hemodialysis patients. Am J Kidney Dis 2004, 44:S61-S67.
23. Baigent C, Landry M: Study of heart and renal protection. Kidney Int 2003, 63:S207-S210.
24. Blum CB: Comparison of properties of four inhibitors of 3-hydroxy-3-methylglutaryl-coenzyme a reductase. Am J Cardiol 1994, 73:3D-11D.
25. Harper CR, Jacobson TA.: Treatment of dyslipidemia in CKD. J Am Coll Cardiol 2008, 51:2375-2384.
26. Koren MJ, Davidson MH: Impact of aggressive treatment with atorvastatin in renal function in managed care patients with coronary heart disease: the ALLIANCE study [abstract]. J Am Coll Cardiol 2005, 45(Suppl A):391A
27. K/DOQI clinical practice guidelines for managing dyslipidemia in chronic kidney disease. Am J Kidney Dis 2003, 41(Suppl 3):S1-S237.
28. National Cholesterol Education Program Expert Panel on Detection: Third report of the National Cholesterol Education Program (NCEP)Expert Panel on detection, evaluation, and treatment of High blood cholesterol in adults (Adult Treatment Panel III) final report. Circulation 2002, 106:3143-421.
29. Brunzell JD, Davidson M, Furberg CD, et al.: Lipoprotein management in patients with cardiometabolic risk: Consensus conference report From the American Diabetes Association and the American College of Cardiology. J Am Coll Cardiol 2008, 51(15):1512-1524.